Bilateral versus unilateral cases of chronic rhinosinusitis with nasal polyps have notable clinical and laboratory differences that impact patient outcomes.
A recent study identified MS4A2 as a key molecule in refractory eosinophilic chronic rhinosinusitis, highlighting MS4A2 as a potential therapeutic target.
The nasal microbiome in CRSwNP, which differs from that of healthy controls, may provide an opportunity to personalize treatment, according to researchers.
Patients have easy access to health information, so doctors must enhance efforts involving helping patients understand their conditions and treatment options.